Imogen Heap · Prevention of Future Deaths report

Pin Get email alerts Request correction

Issued 8 Nov 2024•Blackpool and the Fylde

Published report and response evidence

This report’s concerns and statements found in recipients’ published responses. Statements are included even where no link to an individual concern is recorded. A link shows an evidence connection; it does not assign responsibility.

View original report
Concerns
1

Raised in this report

Recipients
1

Named on the report

Responses found
1

Of 1 recipient

Stated actions
2

Described in responses

Full report text

This is the full text from the original published report.

Open published report

Concerns and recipient responses

Select any concern, action or position to view the source wording.

Report evidence summary

Concerns raised1

  1. Under-appreciation of the risks posed by elevated propranolol medication levels
    Part of recurring concern: Failure to identify clinically significant medication risks

Stated actions An action is something a recipient says it has done, is doing, or plans to do in response to a concern raised.2

  1. National Institute for Health and Care Excellence

    Complete a surveillance review of current evidence and discuss the findings with GP advisors regarding propranolol guidance.

  2. National Institute for Health and Care Excellence

    Review evidence and consult topic experts to consider updating CG113 with a specific recommendation on propranolol for generalised anxiety disorder.

Respondent positions A position is what a recipient says about a concern when it does not describe a specific action.1

  1. National Institute for Health and Care Excellence

    The guideline will not be updated at this time because MHRA found no need for a safety communication and noted widespread safe propranolol use.

    No action considered necessaryThe respondent said that no further action was needed.

Source evidence

How this individual concern was interpreted

PFD Monitor created a concise, searchable interpretation from the report wording shown below. Response links show a clear evidence connection; they do not assign responsibility.

PFD Monitor interpretation

Under-appreciation of the risks posed by elevated propranolol medication levels

Wider context from the report

“My concern is that Propranolol continues to be a drug which is widely prescribed, and often to young people reporting symptoms of anxiety, but that there continues to be an under-appreciation of the level of risk posed by an elevated level of propranolol medication can be. ”

Is this part of a recurring concern?

Yes — Failure to identify clinically significant medication risks.

Open source report

Source evidence

How this respondent action was interpreted

PFD Monitor created a concise, searchable interpretation from the published response wording shown below.

PFD Monitor interpretation

Complete a surveillance review of current evidence and discuss the findings with GP advisors regarding propranolol guidance.

Verbatim wording from the response

“We also outlined that our guidance surveillance team would review any current evidence and consult with topic experts to consider whether an update to CG113 was required, we have now had a surveillance review and discussed with our GP advisors.”

Source location

Update from NICE 10 June 2025
Page 1 · response
Published 13 November 2024

Open published response

Source evidence

How this respondent action was interpreted

PFD Monitor created a concise, searchable interpretation from the published response wording shown below.

PFD Monitor interpretation

Review evidence and consult topic experts to consider updating CG113 with a specific recommendation on propranolol for generalised anxiety disorder.

Verbatim wording from the response

“In response to your report we will review the evidence and consult with topic experts to consider an update to CG113 to make a specific recommendation on whether propranolol should be an option in the treatment pathway for people with generalised anxiety disorder.”

Source location

Response from NICE
Page 1 · response
Published 13 November 2024

Open published response

Source evidence

How this respondent position was interpreted

PFD Monitor created a concise, searchable interpretation from the published response wording shown below.

PFD Monitor interpretation

The guideline will not be updated at this time because MHRA found no need for a safety communication and noted widespread safe propranolol use.

Verbatim wording from the response

“The Medicines & Healthcare products Regulatory Agency (MHRA) have told us that they will not be issuing a drug safety update (DSU) for propranolol. The MHRA stated that ‘The issue of whether or not a DSU was warranted was considered within MHRA in Autumn 2024 and then discussed at one of the monthly DSU planning meetings where a decision was taken not to issue a safety communication. One of the concerns with any communication was inadvertently raising the profile of propranolol overdose. A couple of factors which were taken into consideration are that (i) quite a lot of overdoses with propranolol are mixed overdoses of more than one drug, and that (ii) propranolol is used very widely with millions of items prescribed and used safely each year’. Therefore, our conclusion is that we will not be updating CG113 at this time.”

Source location

Update from NICE 10 June 2025
Page 1 · response
Published 13 November 2024

Open published response
Back to top

Information checked against the published report and official responses · Data reviewed 7 Sep 2026 · About data quality and limitations

Official responses located
1/1

Data last updated 7 September 2026